Trimeris Inc. said it is the target of a patent infringement suit by Novartis Vaccines and Diagnostics Inc. related to manufacture and sale of HIV fusion inhibitor Fuzeon. In a filing with the Securities and Exchange Commission, Trimeris said it was informed Nov. 20 that Novartis filed suit against Hoffman-La Roche Inc., Roche Laboratories Inc., Roche Colorado Corp., and F. Hoffman-La Roche Ltd. and the company alleging infringement of an HIV-related Novartis patent.
November 27, 2007 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Trimeris Inc. said it is the target of a patent infringement suit by Novartis Vaccines and Diagnostics Inc. related to manufacture and sale of HIV fusion inhibitor Fuzeon.
In a filing with the Securities and Exchange Commission, Trimeris said it was informed Nov. 20 that Novartis filed suit against Hoffman-La Roche Inc., Roche Laboratories Inc., Roche Colorado Corp., and F. Hoffman-La Roche Ltd. and the company alleging infringement of an HIV-related Novartis patent.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
